Lusutrombopag - Shionogi

Drug Profile

Lusutrombopag - Shionogi

Alternative Names: MULPLETA; S-888711

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shionogi
  • Class Small molecules; Thiazoles
  • Mechanism of Action Thrombopoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Thrombocytopenia
  • Discontinued Idiopathic thrombocytopenic purpura

Most Recent Events

  • 26 Feb 2018 Lusutrombopag receives priority review status for thrombocytopenia in USA
  • 26 Feb 2018 The European Medicines Agency validates MAA for lusutrombopag for thrombocytopenia
  • 26 Feb 2018 US FDA accepts NDA for lusutrombopag for thrombocytopenia for review
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top